Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders
Rhea-AI Summary
Jaguar Health (NASDAQ:JAGX) reported that stockholders approved all three proposals at the Special Meeting held on December 8, 2025. The company highlighted early clinical and regulatory developments for crofelemer in microvillus inclusion disease (MVID): an investigator-initiated proof-of-concept trial showed crofelemer may extend infant lives and reduce total parenteral support (PS) volumes by up to 37%, though the report notes associated toxicity. Jaguar completed a meeting with the FDA on October 2, 2025 to seek advice on advancing its placebo-controlled crofelemer trial toward a possible expedited approval pathway. CEO Lisa Conte will present updates on December 10, 2025, 3:25–3:35 PM ET at the Emerging Growth Conference.
Positive
- Stockholders approved all three proposals at Dec 8, 2025 meeting
- Investigator trial reported PS reduction of up to 37%
- Company held FDA meeting on Oct 2, 2025 about expedited pathway
Negative
- Initial trial results include associated toxicity in infants
- Clinical data described as initial and from an investigator-initiated study
News Market Reaction – JAGX
In the Dec 9 session, JAGX gained 6.36%, reflecting a notable positive market reaction. Argus tracked a peak move of +19.4% during that session. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 02 | EU regulatory update | Positive | -1.3% | EMA advice request on Canalevia EU approval pathway for canine diarrhea. |
| Nov 24 | Patent and data | Positive | +5.0% | New Australian patent plus early crofelemer PS‑reduction data in SBS and MVID. |
| Nov 20 | Clinical trial protocol | Positive | -8.2% | Amended FDA trial protocol backing possible expedited approval for MVID. |
| Nov 17 | Earnings and update | Negative | +1.4% | Q3 2025 revenue growth but sizable net loss and negative EBITDA reported. |
| Nov 14 | Earnings webcast notice | Neutral | +4.7% | Announcement of timing and access details for Q3 2025 webcast. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has often produced modest and sometimes contrary price reactions, with more divergence than alignment to headline tone.
Over the last month, Jaguar issued multiple updates spanning regulatory, clinical, and financing themes. On Nov 14 and Nov 17, it highlighted Q3 2025 financials and an investor webcast, alongside ongoing losses. Subsequent releases on Nov 20 and Nov 24 detailed crofelemer clinical progress, IP expansion, and investigator-initiated data. On Dec 2, Jaguar outlined its EU pathway for Canalevia in dogs. Today’s approval of all Special Meeting proposals ties directly back to the financing-related proxy items described in these recent filings.
Key Terms
proof-of-concept trial medical
parenteral support medical
microvillus inclusion disease medical
placebo-controlled trial medical
expedited approval pathway regulatory
Special Meeting of Stockholders regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Jaguar CEO Lisa Conte presenting December 10 from 3:25pm - 3:35pm Eastern at the Emerging Growth Conference to provide updates on near-term catalysts; Click here to register
Initial results of ongoing investigator-initiated proof-of-concept trial demonstrate crofelemer can potentially extend the lives of infants born with intestinal failure due to microvillus inclusion disease (MVID), reducing the volume of the total parenteral support (PS) necessary for them to survive, though with associated toxicity; Groundbreaking PS reduction of up to
Company completed meeting with FDA October 2, 2025 for advice on advancing its ongoing placebo-controlled trial of crofelemer in support of possible expedited approval pathway for crofelemer for treatment of MVID
SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 8, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's Special Meeting of Stockholders held on December 8, 2025 (the "Special Meeting").
Three proposals were submitted to and approved by the stockholders of the Company at the Special Meeting. The proposals are described in detail in the Company's definitive proxy statement on Schedule 14A relating to the Special Meeting filed with the Securities and Exchange Commission on November 10, 2025. Stockholders may obtain a free copy of the proxy statement and other documents filed by Jaguar with the SEC at http://www.sec.gov. The proxy statement is also available on the Company's corporate website.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Canalevia-CA1, visit canalevia.com
Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that Jaguar management will present at the December 2025 Emerging Growth Conference, Jaguar's expectation that crofelemer can potentially extend the lives of infants born with intestinal failure due to MVID, reducing the volume of PS necessary for them to survive, and Jaguar's expectation that an expedited approval pathway may be possible for crofelemer for treatment of MVID. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Source: Jaguar Health, Inc.
Contact:
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on ACCESS Newswire